Healthcare Global Enterprises Ltd

Q4 FY26Healthcare Services

Healthcare Global Enterprises Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹726

Market cap₹10.7K Cr

P/E221.4

Updated23 Aug 2026

Read4 min read

The short version

FY26 revenue growth was 15% year-on-year, with broad-based growth across regions. HCG targets around 15% revenue growth over the medium term, supported by 12% patient volume growth and 3% improvement in average revenue per patient (ARPP).

From Healthcare Global Enterprises Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

FY26 revenue growth was 15% year-on-year, with broad-based growth across regions.
Q4 growth impacted by paring down low-margin business and Middle East conflict affecting medical value travel; normalization expected in coming quarters.
Medium-term revenue growth estimate remains close to 15%.
Patient volumes increased by 12% with a 3% improvement in average revenue per patient.
Growth driven by better center utilization, clinical talent additions (23 oncologists added in Q4), and expansion initiatives like North Bangalore and Whitefield.
Expansion via brownfield projects (adding 200+ beds over 24 months in multiple cities) and selective greenfield projects in 10-12 cities under evaluation.
Digital and sales acceleration efforts (doubling Day-Care centers) to support growth.

2 more points management made on revenue & sales performance

Profitability & Margins

HCG targets around 15% revenue growth over the medium term, supported by 12% patient volume growth and 3% improvement in average revenue per patient (ARPP).
The company focuses on profitable, broad-based growth with margin expansion and improving returns rather than merely chasing top-line growth.
Adjusted EBITDA margins improved by 70 basis points to 18.5% in FY26, and management expects further margin expansion driven by operating leverage, better utilization, throughput optimization, and cost discipline.
Pre-tax ROCE improved to 14% in FY26, with a medium-term target of around 20% ROCE within next 4-5 years.
Expansion plans include adding about 1,000 beds by FY30 (400 greenfield, 600 brownfield), bolstering growth and returns.

2 more points management made on profitability & margins

See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Near-term capex focused on brownfield expansions with faster ramp-up and better returns.
Approximately 200+ beds to be added over the next 24 months: 75 in Cuttack, 30 in Ranchi, 50 in Vizag, 20+ in Bhavnagar.
Selective greenfield expansions planned, including North Bangalore and Whitefield facilities; evaluation ongoing for 10-12 additional cities (e.g., Pune, Surat, Coimbatore, Nellore, Lucknow, Jalandhar).
Average brownfield bed addition cost estimated at INR 45 lakh per bed; INR 90-100 crore CAPEX for 200 beds.
Capital raised INR 425 crore rights issue strengthens financial foundation for capacity expansion, clinical infrastructure upgrades, and technology investments.
Asset-light model adopted for new technology like MR-Linac on a pay-per-use basis.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The company successfully completed a rights issue of INR 425 crore, which has strengthened its financial foundation and provided greater flexibility for investments.
The capital raised positions the company well for capacity expansion, clinical infrastructure upgrades, technology investments, and selective growth opportunities.
Management intends to maintain a disciplined, return-focused approach to capital allocation.
There is no specific mention of any immediate or planned new fundraising through debt or equity beyond the recently completed rights issue.

2 more points management made on fundraising & capital structure

See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript does not mention any details regarding the current or expected order book or pending orders for HealthCare Global Enterprises Limited. The discussion primarily focuses on operational performance, expansion plans, financial results, margins, growth strategies, and new facilities such as the North Bangalore facility with the MR-Linac. No references to order book status or pending orders are made in the transcript.

Healthcare Global Enterprises Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹652 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Healthcare Global Enterprises Ltd Q4 FY26 results?

What is Healthcare Global Enterprises Ltd share price analysis?

Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.

Is Healthcare Global Enterprises Ltd planning capital expenditure?

Near-term capex focused on brownfield expansions with faster ramp-up and better returns.

Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.